Currency In USD
| Previous Close | 1.31 |
| Open | 1.29 |
| Day High | 1.37 |
| Day Low | 1.25 |
| 52-Week High | 2.56 |
| 52-Week Low | 0.84 |
| Volume | 23,042.96 |
| Average Volume | 82,670 |
| Market Cap | 6.3M |
| PE | -0.57 |
| EPS | -2.3 |
| Moving Average 50 Days | 1.5 |
| Moving Average 200 Days | 1.44 |
| Change | -0.01 |
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
GlobeNewswire Inc.
Jul 28, 2025 12:00 PM GMT
Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate ATLANTA
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cashIn May 2025, Alzamend dosed the first patient for the healthy human p
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
Capital Raised to Support Five Clinical TrialsATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheime